Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- April30 2004
- Volume 11
- Issue 8
Follow the 'Script
Advertisement
Which pharmaceutical companies hold claim to the industry's drug blockbusters? The following are the world's 10 top-selling prescription drugs for the past year:
Articles in this issue
about 18 years ago
Observe Your Personal Finance Protocolabout 18 years ago
Win the Early Retirement Tax Challengeabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Close-Up: Moldabout 18 years ago
Finding Help to Treat Moldabout 18 years ago
Add Global Flair to Your Life Insuranceabout 18 years ago
Swing Away with the Fat-Pitch Approachabout 18 years ago
Don't Count on Social Security Benefitsabout 18 years ago
Doc's Stocks Contestabout 18 years ago
Know the ABC's of Mutual Fund InvestingAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5